Aarti Drugs

Aarti Drugs, established in 1984, is a prominent entity in the pharmaceutical and healthcare sectors, headquartered in Mumbai, India. The company specializes in the large-scale manufacturing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. Its core API portfolio includes critical compounds such as Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, and Ofloxacin. Additionally, the firm produces specialty chemicals, notably Benzene Sulphonyl Chloride and Methyl Nicotinate, serving diverse industrial applications.

Operating with a workforce of 1,000-5,000 employees, Aarti Drugs maintains a robust operational footprint across 2 distinct locations. The company leverages its technical expertise to maintain high-quality standards in chemical synthesis and pharmaceutical production. With a fiscal year ending on March 31, the organization demonstrates consistent market engagement within the B2B pharmaceutical landscape. Its strategic focus on API manufacturing and specialty chemical synthesis positions it as a key player in the Asian pharmaceutical supply chain, supporting global health initiatives through reliable chemical production.

The organizational structure at Aarti Drugs is supported by a dedicated leadership team focused on operational excellence and technical innovation. Meet Aarti Drugs's team to gain insights into the professional expertise driving the company's strategic initiatives and long-term growth. By prioritizing research and development alongside efficient manufacturing processes, the company continues to expand its influence in the healthcare sector. Aarti Drugs remains committed to delivering high-purity chemical solutions that meet stringent regulatory requirements, ensuring sustained value for its partners and stakeholders across the global pharmaceutical market.